NetworkNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Gains Industry Relevance as FDA Eases Restrictions on Pharmacy-Compounded Peptides, NBC News Reports
This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) is drawing attention amid changes to the regulatory environment for peptide-based treatments, as federal health officials move to allow compounding pharmacies to immediately offer six previously restricted peptides without waiting for formal rulemaking. According to an Oct. 28 NBC News report by Berkeley Lovelace Jr., the Department of Health and Human Services is exercising “enforcement discretion,” temporarily suspending legal action against qualifying pharmacies that compound BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The Food and Drug Administration (“FDA”) is requiring pharmacies to certify the identity and purity of these compounds and report adverse effects, introducing additional safeguards as the administration seeks to shift consumers away from unregulated research-use-only products.
The decision bypasses the usual timeline for adding ingredients to the FDA’s approved compounding list, a process involving proposed regulations, public comments and final rulemaking. While Health and Human Services officials maintain that the approach could improve patient safety by reducing reliance on gray-market peptides, critics, including the Center for Science in the Public Interest and the Partnership for Safe Medicines, warn that the substances lack sufficient evidence of safety and effectiveness. The development highlights the evolving regulatory landscape surrounding peptide therapies and its potential implications for companies operating in the sector, including Adaptogenics Health.
NOTE TO INVESTORS: The latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) is drawing attention amid changes to the regulatory environment for peptide-based treatments, as federal health officials move to allow compounding pharmacies to immediately offer six previously restricted peptides without waiting for formal rulemaking. According to an Oct. 28 NBC News report by Berkeley Lovelace Jr., the Department of Health and Human Services is exercising “enforcement discretion,” temporarily suspending legal action against qualifying pharmacies that compound BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The Food and Drug Administration (“FDA”) is requiring pharmacies to certify the identity and purity of these compounds and report adverse effects, introducing additional safeguards as the administration seeks to shift consumers away from unregulated research-use-only products.
The decision bypasses the usual timeline for adding ingredients to the FDA’s approved compounding list, a process involving proposed regulations, public comments and final rulemaking. While Health and Human Services officials maintain that the approach could improve patient safety by reducing reliance on gray-market peptides, critics, including the Center for Science in the Public Interest and the Partnership for Safe Medicines, warn that the substances lack sufficient evidence of safety and effectiveness. The development highlights the evolving regulatory landscape surrounding peptide therapies and its potential implications for companies operating in the sector, including Adaptogenics Health.
NOTE TO INVESTORS: The latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
